Lexicon Pharmaceuticals, Inc.
LXRX
|
$1.6
-0.62%
-0.63%
1.8M
|
Health Technology
(0.0% 1d) (-19.2% 1m) (-33.6% 1y) (0.0% 2d) (-0.6% 3d) (-3.0% 7d) (-50.49% volume)
Earnings Calendar: 2023-11-09
Market Cap: $ 393,978,805
http://www.lexpharma.com
Sec Filling | Patents | 184 employees
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include XERMELO, Zynquista, and LX9211. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.
diabetic diabetes treatment
Drugs
Xermelo (telotristat ethyl)add to watch list Paper trade email alert is off
Press-releases
Lexicon Pharmaceuticals to Host 2024 Investor Day
Published: 2024-04-18 (Crawled : 12:00) - globenewswire.com
LXRX | $1.6 -0.62% -0.63% 1.8M
|
Health Technology
|
| O: -4.61%
H: 0.0%
C: 0.0%
day pharmaceuticals
Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Published: 2024-04-03 (Crawled : 12:00) - globenewswire.com
LXRX | $1.6 -0.62% -0.63% 1.8M
|
Health Technology
|
| O: 0.45%
H: 0.86%
C: -8.11%
conference pharmaceuticals
Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo
Published: 2024-03-25 (Crawled : 13:00) - globenewswire.com
LXRX | $1.6 -0.62% -0.63% 1.8M
|
Health Technology
|
| O: 0.0%
H: 4.2%
C: -6.19%
stroke risk expo impact heart cardiology
New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease
Published: 2024-03-12 (Crawled : 12:00) - globenewswire.com
LXRX | $1.6 -0.62% -0.63% 1.8M
|
Health Technology
|
| O: 0.36%
H: 0.32%
C: -10.64%
disease kidney control treatment diabetes study
Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update
Published: 2024-03-11 (Crawled : 11:00) - globenewswire.com
LXRX | $1.6 -0.62% -0.63% 1.8M
|
Health Technology
|
| O: 6.91%
H: 21.55%
C: 21.12%
business update pharmaceuticals results
Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities
Published: 2024-03-11 (Crawled : 11:00) - globenewswire.com
LXRX | $1.6 -0.62% -0.63% 1.8M
|
Health Technology
|
| O: 6.91%
H: 21.55%
C: 21.12%
million
Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA
Published: 2024-03-11 (Crawled : 11:00) - globenewswire.com
LXRX | $1.6 -0.62% -0.63% 1.8M
|
Health Technology
|
| O: 6.91%
H: 21.55%
C: 21.12%
fda diabetes
Lexicon Pharmaceuticals Provides Business and Pipeline Update at 42nd Annual J.P. Morgan Healthcare Conference
Published: 2024-01-08 (Crawled : 12:00) - globenewswire.com
LXRX | $1.6 -0.62% -0.63% 1.8M
|
Health Technology
|
| O: 1.69%
H: 3.0%
C: 2.0%
conference business update pipeline pharmaceuticals
Lexicon Pharmaceuticals To Participate In The 42nd Annual JPMorgan Healthcare Conference
Published: 2023-12-21 (Crawled : 21:00) - globenewswire.com
LXRX | $1.6 -0.62% -0.63% 1.8M
|
Health Technology
|
| O: 1.57%
H: 6.2%
C: 1.55%
conference pharmaceuticals
Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
Published: 2023-11-30 (Crawled : 15:30) - biospace.com/
LXRX | $1.6 -0.62% -0.63% 1.8M
|
Health Technology
|
| O: 1.8%
H: 2.65%
C: -6.19%
lx9211 study diabetic
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
| 0000950170-24-031072 | 4 | 2024-03-14 | 2024-03-13 | Buy | A | 1150922 | 1150922 |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Last 48 Hours Insiders Buying
RKT P 347 | $12.55 -0.63% 0.48% 1.7M
|
Finance
|
22:30
NWFL | News | $24.6 2.03% 1.99% 9.9K
|
Finance
|
22:00
TGEN P 10000 | $0.685 39.71% 6.6K
|
Utilities
|
20:01
MNSB P 310 | $15.88 -2.93% -3.02% 46K
|
Finance
|
15:30
RMCF | $3.54 0.28% 7.1K
|
Consumer Non-Durables
|
20:10